Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: Evaluation of transdermal absorption, safety, and pharmacological effects after application in rats

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3230-3238

  Katsumi, Hidemasa ^a   Liu, Shu ^a   Tanaka, Yutaro ^a   Hitomi, Kaori ^a   Hayashi, Rie ^a   Hirai, Yuka ^a   Kusamori, Kosuke ^a   Quan, Ying Shu ^a,b   Kamiyama, Fumio ^b   Sakane, Toshiyasu ^a   Yamamoto, Akira ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b CosMED Pharmaceutical Company Ltd ^*  (Japan)

Author keywords

Absorption; Bioavailability; Pharmacokinetics; Transdermal; transdermal drug delivery

Indexed keywords

ALENDRONIC ACID; HYALURONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; FEMALE; GROWTH PLATE; MALE; MICRONEEDLE ARRAY; NONHUMAN; OSTEOPOROSIS; RAT; SKIN ABSORPTION; SKIN IRRITATION;

EID: 84864039604     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23136     Document Type: Article

References (34)

1. Russell RG. 2011. Bisphosphonates: The first 40 years. Bone 49:12-19.
2. Viera-Negron YE, Ruan W, Winger JN, Hou X, Sharawy MM, Borke JL. 2008. Effect of ovariectomy and alendronate on implant osseointegration in rat maxillary bone. J Oral Implantol 34:76-82.
3. Lambrinoudaki I, Christodoulakos G, Botsis D. 2006. Bisphosphonates. Ann N Y Acad Sci 1092:397-402.
4. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, Papapoulos SE. 2003. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805-811.
5. Porras AG, Holland SD, Gertz BJ. 1999. Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315-328.
6. Graham DY. 2002. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 47:1665-1678.
7. Sener G, Paskaloglu K, Kapucu C, Cetinel S, Contuk G, Ayanog lu-Dulger G. 2004. Octreotide ameliorates alendronate-induced gastric injury. Peptides 25:115-121.
8. Naniwa T, Maeda T, Mizoshita T, Hayami Y, Watanabe M, Banno S, Ito R. 2008. Alendronate-induced esophagitis: Possible pathogenic role of hypersensitivity to alendronate. Intern Med 47:2083-2085.
9. Kusamori K, Katsumi H, Abe M, Ueda A, Sakai R, Hayashi R, Hirai Y, Quan YS, Kamiyama F, Sakane T, Yamamoto A. 2010. Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis. J Bone Miner Res 25:2306-2315.
10. Prausnitz MR. 2004. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56:581-587.
11. Sivamani RK, Liepmann D, Maibach HI. 2007. Microneedles and transdermal applications. Expert Opin Drug Deliv 4:19-25.
12. Arora A, Prausnitz MR, Mitragotri S. 2008. Micro-scale devices for transdermal drug delivery. Int J Pharm 364:227-236.
13. Zhan JD, Talbol NH, Pisano AP, Liepmenn D. 2000. Microfabricated polysilicon microneedles for minimally invasive biomedical devices. Biomed Microdevices 2:295-303.
14. Cormier M, Johnson B, Ameri M, Nyam K, Libiran L, Zhang DD, Daddona P. 2004. Transdermal delivery of desmopressin using a coated microneedle array patch system. J Control Release 97:503-511.
15. Banks SL, Pinninti RR, Gill HS, Paudel KS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. 2010. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci 99:3072-3080.
16. Tas C, Mansoor S, Kalluri H, Zarnitsyn VG, Choi SO, Banga AK, Prausnitz MR. 2012. Delivery of salmon calcitonin using a microneedle patch. Int J Pharm 423:257-263.
17. Park JH, Allen MG, Prausnitz MR. 2005. Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. J Control Release 104:51-66.
18. Ito Y, Yoshimitsu J, Shiroyama K, Sugioka N, Takada K. 2006. Self-dissolving microneedles for the percutaneous absorption of EPO in mice. J Drug Target 14:255-261.
19. Lee JW, Choi SO, Felner EI, Prausnitz MR. 2011. Dissolving microneedle patch for transdermal delivery of human growth hormone. Small 7:531-539.
20. Ding Z, Verbaan FJ, Bivas-Benita M, Bungener L, Huckriede A, van den Berg DJ, Kersten G, Bouwstra JA. 2009. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J Control Release 136:71-78.
21. Wong JA, Renton KW, Crocker JF, O'Regan PA, Acott PD. 2004. Determination of pamidronate in human whole blood and urine by reversed-phase HPLC with fluorescence detection. Biomed Chromatogr 18:98-101.
22. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobiodyn 4:879-885.
23. Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547-558.
24. Xiang A, Kanematsu M, Mitamura M, Kikkawa H, Asano S, Kinoshita M. 2006. Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice. Invest Radiol 41:704-712.
25. Katsumi H, Nakatani M, Sano J, Abe M, Kusamori K, Kurihara M, Shiota R, Takashima M, Fujita T, Sakane T, Hibi T, Yamamoto A. 2010. Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats. Int J Pharm 400:124-130.
26. Katsumi H, Takashima M, Sano J, Nishiyama K, Kitamura N, Sakane T, Hibi T, Yamamoto A. 2011. Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: Evaluation of absorption, safety, and effects after intrapulmonary administration in rats. J Pharm Sci 100:3783-3792.
27. Draize JH, Woodard G, and Calvery HO 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membrane. J Pharmacol Exp Ther 82:377-390.
28. Drake MT, Clarke BL, Khosla S. 2008. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045.
29. Sato M, Grasser W. 1990. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40.
30. Smith WP, Christensen MS, Nacht S, Gans EH. 1982. Effect of lipids on the aggregation and permeability of human stratum corneum. J Invest Dermatol 78:7-11.
31. Li YZ, Quan YS, Zang L, Jin MN, Kamiyama F, Katsumi H, Yamamoto A, Tsutsumi S. 2008. Transdermal delivery of insulin using trypsin as a biochemical enhancer. Biol Pharm Bull 31:1574-1579.
32. Choi A, Gang H, Chun I, Gwak H. 2008. The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm 357:126-131.
33. Bronaugh RL, Stewart RF, Congdon ER. 1982. Methods for in vitro percutaneous absorption studies. II. Animal models for human skin. Toxicol Appl Pharmacol 62:481-488.
34. Takeuchi H, Terasaka S, Sakurai T, Furuya A, Urano H, Sugibayashi K. 2011. Variation assessment for in vitro permeabilities through Yucatan micropig skin. Biol Pharm Bull 34:555-561.